INFLUENCE OF DRUG DELIVERY SYSTEMS ON THE SAFETY ANDEFFECTIVENESS PROFILE OF RIBAVIRIN

MIKHEL I. B.; TITOVA S. A.; BAKHRUSHINA E. O.; STEPANOVA O. I.; KRASNYUK I. I.; SMOLYARCHUK E. A.; KRASNYUK I. I.

doi:10.22159/ijap.2025v17i2.52864

Authors

MIKHEL I. B. Department of Pharmaceutical Technology A.P.Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia https://orcid.org/0000-0002-2866-0049
TITOVA S. A. I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia https://orcid.org/0009-0009-8457-0222
BAKHRUSHINA E. O. Department of Pharmaceutical Technology A.P.Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia https://orcid.org/0000-0001-8695-0346
STEPANOVA O. I. Department of Pharmacology A.P.Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
KRASNYUK I. I. I.M. Sechenov First Moscow State Medical University (Sechenov University)
SMOLYARCHUK E. A. Department of Pharmacology A.P.Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia https://orcid.org/0000-0002-2615-7167
KRASNYUK I. I. I.M. Sechenov First Moscow State MeDepartment of Pharmaceutical Technology, A.P. Nelyubin Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russiadical University (Sechenov University)

DOI:

https://doi.org/10.22159/ijap.2025v17i2.52864

Keywords:

Ribavirin, Drug delivery systems, Excipients, Side effects, Hemolytic anemia, Bioavailability

Abstract

Ribavirin is an antiviral drug with a wide spectrum of pharmacological activity. The development of drug delivery systems that increase the safety and effectiveness of ribavirin has been the subject of scientific research for decades. The aim of this article is to examine the published information on this topic, evaluate it according to several criteria, and outline the primary perspectives on this subject within the fields of pharmacy and pharmacology. The results of the evaluation indicate that, despite the extensive and ongoing discourse surrounding the potential modifications to ribavirin within the international scientific community, the majority of publications adopt an illustrative approach. Many relevant and promising applied studies require further development, comprehensive biopharmaceutical indicator testing, rigorous clinical efficacy assessment, and a thorough evaluation of patient compliance.

Downloads

Download data is not yet available.

References

Mejer N, Galli A, Ramirez S, Fahnøe U, Benfield T, Bukh J. Ribavirin inhibition of cell-culture infectious hepatitis C genotype 1-3 viruses is strain-dependent. Virology. 2020 Jan 15;540:132-140. doi: 10.1016/j.virol.2019.09.014. Epub 2019 Sep 28. PMID: 31778898.

Kamar N, Abravanel F, Behrendt P, Hofmann J, Pageaux GP, Barbet C, Moal V, Couzi L, Horvatits T, De Man RA, Cassuto E, Elsharkawy AM, Riezebos-Brilman A, Scemla A, Hillaire S, Donnelly MC, Radenne S, Sayegh J, Garrouste C, Dumortier J, Glowaki F, Matignon M, Coilly A, Figueres L, Mousson C, Minello A, Dharancy S, Rerolle JP, Lebray P, Etienne I, Perrin P, Choi M, Marion O, Izopet J; Hepatitis E Virus Ribavirin Study Group. Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. Clin Infect Dis. 2020 Aug 22;71(5):1204-1211. doi: 10.1093/cid/ciz953. PMID: 31793638.

Salam AP, Duvignaud A, Jaspard M, Malvy D, Carroll M, Tarning J, Olliaro PL, Horby PW. Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing. PLoSNegl Trop Dis. 2022 Mar 30;16(3):e0010289. doi: 10.1371/journal.pntd.0010289. PMID: 35353804; PMCID: PMC9000057.

Eberhardt KA, Mischlinger J, Jordan S, Groger M, Günther S, Ramharter M. Ribavirin for the treatment of Lassa fever: A systematic review and meta-analysis. Int J Infect Dis. 2019 Oct;87:15-20. doi: 10.1016/j.ijid.2019.07.015. Epub 2019 Jul 26. PMID: 31357056.

Mayor J, Engler O, Rothenberger S. Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus. Microorganisms. 2021 Jun 15;9(6):1306. doi: 10.3390/microorganisms9061306. PMID: 34203936; PMCID: PMC8232603.

Tejada S, Martinez-Reviejo R, Karakoc HN, Peña-López Y, Manuel O, Rello J. Ribavirin for Treatment of Subjects with Respiratory Syncytial Virus-Related Infection: A Systematic Review and Meta-Analysis. Adv Ther. 2022 Sep;39(9):4037-4051. doi: 10.1007/s12325-022-02256-5. Epub 2022 Jul 25. PMID: 35876973.

Poulakou G, Barakat M, Israel RJ, Bacci MR; Virazole Collaborator Group for COVID-19 Respiratory Distress. Ribavirin aerosol in hospitalized adults with respiratory distress and COVID-19: An open-label trial. Clin Transl Sci. 2023 Jan;16(1):165-174. doi: 10.1111/cts.13436. Epub 2022 Nov 3. PMID: 36326174; PMCID: PMC9841304.

Unal MA, Bitirim CV, Summak GY, Bereketoglu S, CevherZeytin I, Besbinar O, Gurcan C, Aydos D, Goksoy E, Kocakaya E, Eran Z, Murat M, Demir N, Aksoy Ozer ZB, Somers J, Demir E, Nazir H, Ozkan SA, Ozkul A, Azap A, Yilmazer A, Akcali KC. Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro. Can J PhysiolPharmacol. 2021 May;99(5):449-460. doi: 10.1139/cjpp-2020-0734. Epub 2021 Mar 9. PMID: 33689451.

Janowski AB, Dudley H, Wang D. Antiviral activity of ribavirin and favipiravir against human astroviruses. J Clin Virol. 2020 Feb;123:104247. doi: 10.1016/j.jcv.2019.104247. Epub 2019 Dec 17. PMID: 31864069; PMCID: PMC7034780.

Huq S, Casaos J, Serra R, Peters M, Xia Y, Ding AS, Ehresman J, Kedda JN, Morales M, Gorelick NL, Zhao T, Ishida W, Perdomo-Pantoja A, Cecia A, Ji C, Suk I, Sidransky D, Brait M, Brem H, Skuli N, Tyler B. Repurposing the FDA-Approved Antiviral Drug Ribavirin as Targeted Therapy for Nasopharyngeal Carcinoma. Mol Cancer Ther. 2020 Sep;19(9):1797-1808. doi: 10.1158/1535-7163.MCT-19-0572. Epub 2020 Jun 30. PMID: 32606016.

Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R, Felder R, Lott T, Kast RE, Suk I, Brem H, Tyler B, Skuli N. The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral? Mol Cancer Ther. 2019 Jul;18(7):1185-1194. doi: 10.1158/1535-7163.MCT-18-0666. PMID: 31263027.

Zhu S, Han X, Yang R, Tian Y, Zhang Q, Wu Y, Dong S, Zhang B. Metabolomics study of ribavirin in the treatment of orthotopic lung cancer based on UPLC-Q-TOF/MS. Chem Biol Interact. 2023 Jan 25;370:110305. doi: 10.1016/j.cbi.2022.110305. Epub 2022 Dec 16. PMID: 36529159.

Burman B, Drutman SB, Fury MG, Wong RJ, Katabi N, Ho AL, Pfister DG. Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. Oral Oncol. 2022 May;128:105806. doi: 10.1016/j.oraloncology.2022.105806. Epub 2022 Mar 23. PMID: 35339025; PMCID: PMC9788648.

Wambecke A, Laurent-Issartel C, Leroy-Dudal J, Giffard F, Cosson F, Lubin-Germain N, Uziel J, Kellouche S, Carreiras F. Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells. PLoS One. 2019 Dec 11;14(12):e0225860. doi: 10.1371/journal.pone.0225860. PMID: 31825993; PMCID: PMC6905583.

Zhang Q, Yang R, Tian Y, Ge S, Nan X, Zhu S, Dong S, Zhang B. Ribavirin inhibits cell proliferation and metastasis and prolongs survival in soft tissue sarcomas by downregulating both protein arginine methyltransferases 1 and 5. Basic Clin PharmacolToxicol. 2022 Jul;131(1):18-33. doi: 10.1111/bcpt.13736. Epub 2022 May 6. PMID: 35470570.

Petković B, Kesić S, Pešić V. Critical View on the Usage of Ribavirin in Already Existing Psychostimulant-Use Disorder. Curr Pharm Des. 2020;26(4):466-484. doi: 10.2174/1381612826666200115094642. PMID: 31939725; PMCID: PMC8383468.

Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol. 2009 Feb;50(2):402-11. doi: 10.1016/j.jhep.2008.11.006. Epub 2008 Dec 3. PMID: 19091439.

Shiffman ML. What future for ribavirin? Liver Int. 2009 Jan;29 Suppl 1:68-73. doi: 10.1111/j.1478-3231.2008.01936.x. PMID: 19207968.

Barrail-Tran A, Goldwirt L, Gelé T, Laforest C, Lavenu A, Danjou H, Radenne S, Leroy V, Houssel-Debry P, Duvoux C, Kamar N, De Ledinghen V, Canva V, Conti F, Durand F, D'Alteroche L, Botta-Fridlund D, Moreno C, Cagnot C, Samuel D, Fougerou-Leurent C, Pageaux GP, Duclos-Vallée JC, Taburet AM, Coilly A. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. Eur J Clin Pharmacol. 2019 Nov;75(11):1555-1563. doi: 10.1007/s00228-019-02725-x. Epub 2019 Aug 5. PMID: 31384986.

Preston SL, Drusano GL, Glue P, Nash J, Gupta SK, McNamara P. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother. 1999 Oct;43(10):2451-6. doi: 10.1128/AAC.43.10.2451. PMID: 10508023; PMCID: PMC89499.

Chen R, Wang T, Song J, Pu D, He D, Li J, Yang J, Li K, Zhong C, Zhang J. Antiviral Drug Delivery System for Enhanced Bioactivity, Better Metabolism and Pharmacokinetic Characteristics. Int J Nanomedicine. 2021 Jul 22;16:4959-4984. doi: 10.2147/IJN.S315705. PMID: 34326637; PMCID: PMC8315226.

Guo H, Sun S, Yang Z, Tang X, Wang Y. Strategies for ribavirin prodrugs and delivery systems for reducing the side-effect hemolysis and enhancing their therapeutic effect. J Control Release. 2015 Jul 10;209:27-36. doi: 10.1016/j.jconrel.2015.04.016. Epub 2015 Apr 14. PMID: 25883028.

Elberry MH, Darwish NHE, Mousa SA. Hepatitis C virus management: potential impact of nanotechnology. Virol J. 2017 May 2;14(1):88. doi: 10.1186/s12985-017-0753-1. PMID: 28464951; PMCID: PMC5414367.

Abd Ellah NH, Tawfeek HM, John J, Hetta HF. Nanomedicine as a future therapeutic approach for Hepatitis C virus. Nanomedicine (Lond). 2019 Jun;14(11):1471-1491. doi: 10.2217/nnm-2018-0348. Epub 2019 Jun 5. PMID: 31166139.

Nader K, Shetta A, Saber S, Mamdouh W. The potential of carbon-based nanomaterials in hepatitis C virus treatment: a review of carbon nanotubes, dendrimers and fullerenes. Discov Nano. 2023 Sep 16;18(1):116. doi: 10.1186/s11671-023-03895-5. PMID: 37715929; PMCID: PMC10505122.

Di Stefano G, Busi C, Mattioli A, Fiume L. Selective delivery to the liver of antiviral nucleoside analogs coupled to a high molecular mass lactosaminated poly-L-lysine and administered to mice by intramuscular route. BiochemPharmacol. 1995 Jun 16;49(12):1769-75. doi: 10.1016/0006-2952(95)00020-z. PMID: 7541203.

Fiume L, Busi C, G. Stefano Di, Mattioli A. Targeting of antiviral drugs to the liver using glycoprotein carriers, Advanced Drug Delivery Reviews,Volume 14, Issue 1,1994, Pages 51-65, ISSN 0169-409X, https://doi.org/10.1016/0169-409X(94)90005-1.

Dong Z, Li Q, Guo D, Shu Y, Polli JE. Synthesis and Evaluation of Bile Acid-Ribavirin Conjugates as Prodrugs to Target the Liver. J Pharm Sci. 2015 Sep;104(9):2864-76. doi: 10.1002/jps.24375. Epub 2015 Feb 2. PMID: 25645375; PMCID: PMC4522399.

Hashim F, El-Ridy M, Nasr M, Abdallah Y. Preparation and characterization of niosomes containing ribavirin for liver targeting. Drug Deliv. 2010 Jul;17(5):282-7. doi: 10.3109/10717541003706257. PMID: 20350052.

Schekman R, Singer SJ. Clustering and endocytosis of membrane receptors can be induced in mature erythrocytes of neonatal but not adult humans. Proc Natl Acad Sci USA. 1976;73:4075–9. 45.

Rothen-Rutishauser BM, Schurch S, Haenni B, Kapp N, Gehr P. Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic techniques. Environ Sci Technol. 2006;40:4353–9.

Abo‐zeid Y, Irving W, Thomson B, Mantovani G, Garnett M. P19: Ribavirin‐ boronic acid loaded nanoparticles: a possible route to improve hepatitis C treatment. J Viral Hepatitis. 2013;20:26–7.

Ishihara T, Kaneko K, Ishihara T, Mizushima T. Development of biodegradable nanoparticles for liver-specific ribavirin delivery. J Pharm Sci. 2014;103:4005–11.

Virovic L, Wu CH, Konishi M, Wu GY. Novel delivery methods for treatment of viral hepatitis: an update. Expert Opin Drug Deliv. 2005 Jul;2(4):707-17. doi: 10.1517/17425247.2.4.707. PMID: 16296795.

Wohl BM, Smith AA, Jensen BE, Zelikin AN. Macromolecular (pro)drugs with concurrent direct activity against the hepatitis C virus and inflammation. J Control Release. 2014 Dec 28;196:197-207. doi: 10.1016/j.jconrel.2014.09.032. Epub 2014 Oct 16. PMID: 25451544.

Chiani E, Beaucamp A, Hamzeh Y, Azadfallah M, Thanusha AV, Collins MN. Synthesis and characterization of gelatin/lignin hydrogels as quick release drug carriers for Ribavirin. Int J Biol Macromol. 2023 Jan 1;224:1196-1205. doi: 10.1016/j.ijbiomac.2022.10.205. Epub 2022 Oct 26. PMID: 36309240.

Kende M, Alving CR, Rill WL, Swartz GM Jr, Canonico PG. Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice. Antimicrob Agents Chemother. 1985 Jun;27(6):903-7. doi: 10.1128/AAC.27.6.903. PMID: 4026264; PMCID: PMC180183.

Bialasek M, Kubiak M, Gorczak M, Braniewska A, Kucharzewska-Siembieda P, Krol M, Taciak B. Exploiting iron-binding proteins for drug delivery. J PhysiolPharmacol. 2019 Oct;70(5). doi: 10.26402/jpp.2019.5.03. Epub 2019 Dec 26. PMID: 31889039.

Brookes S, Biessels P, Ng NF, Woods C, Bell DN, Adamson G. Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery. Bioconjug Chem. 2006 Mar-Apr;17(2):530-7. doi: 10.1021/bc0503317. PMID: 16536487.

Levy GA, Adamson G, Phillips MJ, Scrocchi LA, Fung L, Biessels P, Ng NF, Ghanekar A, Rowe A, Ma MX, Levy A, Koscik C, He W, Gorczynski R, Brookes S, Woods C, McGilvray ID, Bell D. Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity. Hepatology. 2006 Mar;43(3):581-91. doi: 10.1002/hep.21072. PMID: 16496340; PMCID: PMC7165489.

Riber CF, Hinton TM, Gajda P, Zuwala K, Tolstrup M, Stewart C, Zelikin AN. Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity. Mol Pharm. 2017 Jan 3;14(1):234-241. doi: 10.1021/acs.molpharmaceut.6b00826. Epub 2016 Nov 23. PMID: 28043136.

Shigeta S, Mori S, Watanabe J, Soeda S, Takahashi K, Yamase T. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob Agents Chemother. 1997 Jul;41(7):1423-7. doi: 10.1128/AAC.41.7.1423. PMID: 9210659; PMCID: PMC163933.

Gangemi JD, Nachtigal M, Barnhart D, Krech L, Jani P. Therapeutic efficacy of liposome-encapsulated ribavirin and muramyl tripeptide in experimental infection with influenza or herpes simplex virus. J Infect Dis. 1987 Mar;155(3):510-7. doi: 10.1093/infdis/155.3.510. PMID: 3805775.

Dumont EF, Oliver AJ, Ioannou C, Billiard J, Dennison J, van den Berg F, Yang S, Chandrasekaran V, Young GC, Lahiry A, Starbuck DC, Harrell AW, Georgiou A, Hopchet N, Gillies A, Baker SJ. A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02267-19. doi: 10.1128/AAC.02267-19. PMID: 32071044; PMCID: PMC7179635.

Ibrahim MM, Maria DN, Wang X, Simpson RN, Hollingsworth TJ, Jablonski MM. Enhanced Corneal Penetration of a Poorly Permeable Drug Using Bioadhesive Multiple Microemulsion Technology. Pharmaceutics. 2020 Jul 26;12(8):704. doi: 10.3390/pharmaceutics12080704. PMID: 32722550; PMCID: PMC7463957.

Li X, Pan W, Ju C, Liu Z, Pan H, Zhang H, Nie S. Evaluation of Pharmasolve corneal permeability enhancement and its irritation on rabbit eyes. Drug Deliv. 2009 May;16(4):224-9. doi: 10.1080/10717540902850567. PMID: 19514982.

Liu R, Liu Z, Zhang C, Zhang B. Gelucire44/14 as a novel absorption enhancer for drugs with different hydrophilicities: in vitro and in vivo improvement on transcorneal permeation. J Pharm Sci. 2011 Aug;100(8):3186-3195. doi: 10.1002/jps.22540. Epub 2011 Mar 17. PMID: 21416467.

Lai CH, Yang YH, Chen PC, King YC, Liu CY. Retinal vascular complications associated with interferon-ribavirin therapy for chronic hepatitis C: A population-based study. Pharmacoepidemiol Drug Saf. 2018 Feb;27(2):191-198. doi: 10.1002/pds.4363. Epub 2017 Dec 6. PMID: 29210149.

Elgouhary SM, Said-Ahmed KE, Mowafy MA. Anatomical and Functional Retinal Complications of Combined Sofosbuvir and Ribavirin Therapy in Patients With Chronic Hepatitis C Virus. Ophthalmic Surg Lasers Imaging Retina. 2019 Jan 1;50(1):39-41. doi: 10.3928/23258160-20181212-06. PMID: 30640394.

Abd Elaziz MS, Nada ASE, ElSayed SH, Nasr GS, Zaky AG. Ocular comorbidities with direct-acting antiviral treatment for chronic hepatitis C virus (HCV) patients. Int Ophthalmol. 2020 May;40(5):1245-1251. doi: 10.1007/s10792-020-01290-y. Epub 2020 Jan 21. PMID: 31965393.

Jeulin H, Venard V, Carapito D, Finance C, Kedzierewicz F. Effective ribavirin concentration in mice brain using cyclodextrin as a drug carrier: evaluation in a measles encephalitis model. Antiviral Res. 2009 Mar;81(3):261-6. doi: 10.1016/j.antiviral.2008.12.006. Epub 2009 Jan 6. PMID: 19133295.

Sengupta S, Paul P, Mukherjee B, Gaonkar RH, Debnath MC, Chakraborty R, Khatun N, Roy S. Peripheral nerve targeting by procaine-conjugated ribavirin-loaded dual drug nanovesicle. Nanomedicine (Lond). 2018 Dec;13(23):3009-3023. doi: 10.2217/nnm-2018-0192. Epub 2018 Dec 3. PMID: 30507340.

Colombo G, Lorenzini L, Zironi E, Galligioni V, Sonvico F, Balducci AG, Pagliuca G, Giuliani A, Calzà L, Scagliarini A. Brain distribution of ribavirin after intranasal administration. Antiviral Res. 2011 Dec;92(3):408-14. doi: 10.1016/j.antiviral.2011.09.012. Epub 2011 Oct 6. PMID: 22001322.

Giuliani A, Balducci AG, Zironi E, Colombo G, Bortolotti F, Lorenzini L, Galligioni V, Pagliuca G, Scagliarini A, Calzà L, Sonvico F. In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates. Drug Deliv. 2018 Nov;25(1):376-387. doi: 10.1080/10717544.2018.1428242. PMID: 29382237; PMCID: PMC6058489.

Vasa DM, Bakri Z, Donovan MD, O'Donnell LA, Wildfong PLD. Evaluation of Ribavirin-Poloxamer Microparticles for Improved Intranasal Absorption. Pharmaceutics. 2021 Jul 23;13(8):1126. doi: 10.3390/pharmaceutics13081126. PMID: 34452087; PMCID: PMC8399989.

Loginova S.J., Shchukina V.N., Borisevich S.V. The Modern State of Prevention and Treatment of Chikungunya Fever. AntibiotKhimioter = Antibiotics and Chemotherapy. 2020;65(3-4):45-53. (In Russ.) https://doi.org/10.37489/0235-2990-2020-65-3-4-45-53.

Zhurkin MA, Ivanov VV, Kharitonov MA, Saluchov V.V., Zhogolev K.D., Zhogolev S.D., Sboychakov V.B. THE USE OF RIBAVIRINUM IN COMPLEX THERAPY OF VIRUS-BACTERIAL PNEUMONIA. “Russian-Chinese scientific-practical conference on medical microbiology and clinical mycology (ХIХKashkinskiye readings). Theses of reports” Problems of medical mycology, vol. 18, no. 2, 2016, pp. 34-131.

Shilovskiy IP, Yumashev KV, Kozhikhova Ksenia. Vishniakova LI, Smirnov VV, Gudima GO, Brylina VE, Kaganova MM, Nikolskii AA, Barvinskaia ED, KovchinaVI, Rusak TE, ShatilovaAnastasiia, Shatilov Artem, Andreev Sergey Kudlay DA, Khaitov Musa. (2023). A synthetic peptide mimicking the antigenic site of F protein suppresses of respiratory syncytial virus infection in vitro. Immunologiya. 44. 134-146. 10.33029/0206-4952-2023-44-2-134-146.

Postnov V.N., Naumysheva E.B., Korolev D.V., Galagudza M.M. Nanoscale carriers for drug delivery // Biotechnosphere. 2013. №6 (30). URL: https://cyberleninka.ru/article/n/nanorazmernye-nositeli-dlya-dostavki-lekarstvennyh-preparatov (Date of access: 31.03.2024).

Chekhonin VP, Merkulov VA, Kuznetsov DA, Petrov AA, Pavlyuk AS Prospects for the application of nanobiotechnology in medicine // Bulletin of Russian State Medical University. 2009. №1. URL: https://cyberleninka.ru/article/n/perspektivy-primeneniya-nanobiotehnologii-v-meditsine (Date of access: 31.03.2024).

Yamansarov EY, Petrov RA, Petrov SA, Saltykova IV, Ondar EE, Kislyakov IV, Beloglazkina EK, Zyk NV, Kotelansky VE, Mazhuga AG Low-molecular glycoconjugates antiviral drug ribavirin with galactosamine derivatives - a new approach to targeted therapy of liver diseases // Russian Biotherapeutic Journal. 2017. №S1. URL: https://cyberleninka.ru/article/n/nizkomolekulyarnye-glikokonyugaty-protivovirusnogo-preparata-ribavirin-s-proizvodnymi-galaktozamina-novyy-podhod-adresnoy-terapii (Date of access: 31.03.2024).

Bakhrushina E.O., Ivkina A.S., Tabanskaya T.V. Evaluation of biopharmaceutical indicators of a new intranasal antiviral drug based on in situ system // Health and Education in the XXI century. 2023. №4. URL: https://cyberleninka.ru/article/n/otsenka-biofarmatsevticheskih-pokazateley-novogo-intranazalnogo-protivovirusnogo-preparata-na-osnove-in-situ-sistemy (дата обращения: 31.03.2024).

Usova S. V., Targonsky SN, Zemskova L. N., Zmyzgova A. V., Isaeva NP. V., Isaeva N. P. Experience with a new regimen for the treatment of chronic viral hepatitis using liposomal form of ribavirin // ZV. 2012. №4. URL: https://cyberleninka.ru/article/n/opyt-primeneniya-novoy-shemy-lecheniya-hronicheskogo-virusnogo-gepatita-s-s-ispolzovaniem-liposomalnoy-formy-ribavirina (Date of access: 31.03.2024).

Glotova TI, Nikonova AA, Glotov AG Antiviral compounds and drugs effective against bovine viral diarrhea virus // Voprosyvirosologii. 2017. №5. URL: https://cyberleninka.ru/article/n/protivovirusnye-soedineniya-i-preparaty-effektivnye-v-otnoshenii-virusa-virusnoy-diarei-krupnogo-rogatogo-skota (Date of access: 31.03.2024).

Mendez R. Sonication-Based Basic Protocol for Liposome Synthesis. Methods Mol Biol. 2023;2625:365-370. doi: 10.1007/978-1-0716-2966-6_31. PMID: 36653658.

Almeida B, Nag OK, Rogers KE, Delehanty JB. Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery. Molecules. 2020 Dec 1;25(23):5672. doi: 10.3390/molecules25235672. PMID: 33271886; PMCID: PMC7730700.

Wang Y. Liposome as a delivery system for the treatment of biofilm-mediated infections. J Appl Microbiol. 2021 Dec;131(6):2626-2639. doi: 10.1111/jam.15053. Epub 2021 Mar 12. PMID: 33650748.

Gorain B, Al-Dhubiab BE, Nair A, Kesharwani P, Pandey M, Choudhury H. Multivesicular Liposome: A Lipid-based Drug Delivery System for Efficient Drug Delivery. Curr Pharm Des. 2021;27(43):4404-4415. doi: 10.2174/1381612827666210830095941. PMID: 34459377.

Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021 Sep;176:113851. doi: 10.1016/j.addr.2021.113851. Epub 2021 Jul 2. PMID: 34224787.

Lima PHC, Butera AP, Cabeça LF, Ribeiro-Viana RM. Liposome surface modification by phospholipid chemical reactions. Chem Phys Lipids. 2021 Jul;237:105084. doi: 10.1016/j.chemphyslip.2021.105084. Epub 2021 Apr 20. PMID: 33891960.

Meng Y, Niu X, Li G. Liposome Nanoparticles as a Novel Drug Delivery System for Therapeutic and Diagnostic Applications. Curr Drug Deliv. 2022;20(1):41-56. doi: 10.2174/1567201819666220324093821. PMID: 35331112.

Has C, Sunthar P. A comprehensive review on recent preparation techniques of liposomes. J Liposome Res. 2020 Dec;30(4):336-365. doi: 10.1080/08982104.2019.1668010. Epub 2019 Sep 27. PMID: 31558079.

Gan Y, Yu Y, Xu H, Piao H. Liposomal Nanomaterials: A Rising Star in Glioma Treatment. Int J Nanomedicine. 2024 Jul 5;19:6757-6776. doi: 10.2147/IJN.S470478. PMID: 38983132; PMCID: PMC11232959.

Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y. Liposomes: Advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154-155:102-122. doi: 10.1016/j.addr.2020.07.002. Epub 2020 Jul 8. PMID: 32650041.

Guimarães D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021 May 15;601:120571. doi: 10.1016/j.ijpharm.2021.120571. Epub 2021 Apr 2. PMID: 33812967.

Inal O, Amasya G, SezginBayindir Z, Yuksel N. Development and quality assessment of glutathione tripeptide loaded niosome containing carbopolemulgels as nanocosmeceutical formulations. Int J Biol Macromol. 2023 Jun 30;241:124651. doi: 10.1016/j.ijbiomac.2023.124651. Epub 2023 Apr 28. PMID: 37119885.

Farmoudeh A, Akbari J, Saeedi M, Ghasemi M, Asemi N, Nokhodchi A. Methylene blue-loaded niosome: preparation, physicochemical characterization, and in vivo wound healing assessment. Drug DelivTransl Res. 2020 Oct;10(5):1428-1441. doi: 10.1007/s13346-020-00715-6. PMID: 32100265; PMCID: PMC7447683.

Kheilnezhad B, Hadjizadeh A. Factors Affecting the Penetration of Niosome into the Skin, Their Laboratory Measurements and Dependency to the Niosome Composition: A Review. Curr Drug Deliv. 2021;18(5):555-569. doi: 10.2174/1567201817999200820161438. PMID: 32842940.

Barani M, Paknia F, Roostaee M, Kavyani B, Kalantar-Neyestanaki D, Ajalli N, Amirbeigi A. Niosome as an Effective Nanoscale Solution for the Treatment of Microbial Infections. Biomed Res Int. 2023 Aug 16;2023:9933283. doi: 10.1155/2023/9933283. PMID: 37621700; PMCID: PMC10447041.

Lai X, Chow SH, Le Brun AP, Muir BW, Bergen PJ, White J, Yu HH, Wang J, Danne J, Jiang JH, Short FL, Han ML, Strugnell RA, Song J, Cameron NR, Peleg AY, Li J, Shen HH. Polysaccharide-Targeting Lipid Nanoparticles to Kill Gram-Negative Bacteria. Small. 2024 Feb;20(6):e2305052. doi: 10.1002/smll.202305052. Epub 2023 Oct 5. PMID: 37798622.

Rezaei H, Iranbakhsh A, Sepahi AA, Mirzaie A, Larijani K. Formulation, preparation of niosome loaded zinc oxide nanoparticles and biological activities. Sci Rep. 2024 Jul 19;14(1):16692. doi: 10.1038/s41598-024-67509-5. PMID: 39030347; PMCID: PMC11271597.

Hedayati Ch M, AbolhassaniTarghi A, Shamsi F, Heidari F, Salehi Moghadam Z, Mirzaie A, Behdad R, Moghtaderi M, Akbarzadeh I. Niosome-encapsulated tobramycin reduced antibiotic resistance and enhanced antibacterial activity against multidrug-resistant clinical strains of Pseudomonas aeruginosa. J Biomed Mater Res A. 2021 Jun;109(6):966-980. doi: 10.1002/jbm.a.37086. Epub 2020 Aug 31. PMID: 32865883.

Rahmati M, Babapoor E, Dezfulian M. Amikacin-loaded niosome nanoparticles improve amikacin activity against antibiotic-resistant Klebsiella pneumoniae strains. World J MicrobiolBiotechnol. 2022 Oct 3;38(12):230. doi: 10.1007/s11274-022-03405-2. PMID: 36184645; PMCID: PMC9527143.

Ergin AD, Oltulu Ç, Türker NP, Demirbolat GM. In vitro hepatotoxicity evaluation of methotrexate-loaded niosome formulation: fabrication, characterization and cell culture studies. Turk J Med Sci. 2023 Aug;53(4):872-882. doi: 10.55730/1300-0144.5651. Epub 2023 Aug 18. PMID: 38031943; PMCID: PMC10760534.

Salehi S, Nourbakhsh MS, Yousefpour M, Rajabzadeh G, Sahab-Negah S. Chitosan-coated niosome as an efficient curcumin carrier to cross the blood-brain barrier: an animal study. J Liposome Res. 2022 Sep;32(3):284-292. doi: 10.1080/08982104.2021.2019763. Epub 2021 Dec 26. PMID: 34957899.

Sharma S, Kumari N, Garg D, Chauhan S. A Compendium of Bioavailability Enhancement via Niosome Technology. Pharm Nanotechnol. 2023;11(4):324-338. doi: 10.2174/2211738511666230309104323. PMID: 36892113.

Obeid MA, Teeravatcharoenchai T, Connell D, Niwasabutra K, Hussain M, Carter K, Ferro VA. Examination of the effect of niosome preparation methods in encapsulating model antigens on the vesicle characteristics and their ability to induce immune responses. J Liposome Res. 2021 Jun;31(2):195-202. doi: 10.1080/08982104.2020.1768110. Epub 2020 May 28. PMID: 32396752.

Tao R, Liu L, Xiong Y, Zhang Q, Lv X, He L, Ren F, Zhou L, Chen B, Wu K, Zhang Y, Chen H. Construction and evaluation of a phospholipid-based phase transition in situ gel system for brexpiprazole. Drug DelivTransl Res. 2023 Nov;13(11):2819-2833. doi: 10.1007/s13346-023-01349-0. Epub 2023 May 9. PMID: 37160629.

RIYA V KALEBAR, PANKAJ GAJARE, MAMLE DESAI SN, VISHAL U KALEBAR, RAVINDRANATH H ALADAKATTI. SYNERGISTIC DRUG COMPATIBILITY OF SUMATRIPTAN SUCCINATE AND METOCLOPRAMIDE HYDROCHLORIDE (IN SITU GEL FORMULATIONS) FOR NASAL DRUG RELEASE OPTIMIZATION. Asian Journal of Pharmaceutical and Clinical Research. 2024 Mar 7;132–8.

SINGH M, DEV D. ACACIA CATACHU GUM IN SITU FORMING GELS WITH PROLONGED RETENTION TIME FOR OCULAR DRUG DELIVERY. Asian Journal of Pharmaceutical and Clinical Research. 2022 Sep 7;33–40.

AMBIKAR RB, BHOSALE A V. DEVELOPMENT AND CHARACTERIZATION OF DICLOFENAC SODIUM LOADED EUDRAGIT RS100 POLYMERIC MICROSPONGE INCORPORATED INTO IN SITU GEL FOR OPHTHALMIC DRUG DELIVERY SYSTEM. Int J Pharm Pharm Sci. 2021 Sep 1;63–9.

REDDY MS, BEGUM Z. FORMULATION AND IN VITRO EVALUATION OF GASTRO RETENTIVE IN-SITU FLOATING GELS OF TELMISARTAN CUBOSOMES. Int J Curr Pharm Res. 2022 Jan 15;44–53.

Ourani-Pourdashti S, Mirzaei E, Heidari R, Ashrafi H, Azadi A. Preparation and evaluation of niosomal chitosan-based in situ gel formulation for direct nose-to-brain methotrexate delivery. Int J Biol Macromol. 2022 Jul 31;213:1115-1126. doi: 10.1016/j.ijbiomac.2022.06.031. Epub 2022 Jun 9. PMID: 35691430.

Mohanty D, Alsaidan OA, Zafar A, Dodle T, Gupta JK, Yasir M, Mohanty A, Khalid M. Development of Atomoxetine-Loaded NLC In Situ Gel for Nose-to-Brain Delivery: Optimization, In Vitro, and Preclinical Evaluation. Pharmaceutics. 2023 Jul 20;15(7):1985. doi: 10.3390/pharmaceutics15071985. PMID: 37514171; PMCID: PMC10386213.

Gattani V, Dawre S. Development of favipiravir loaded PLGA nanoparticles entrapped in in-situ gel for treatment of Covid-19 via nasal route. J Drug Deliv Sci Technol. 2023 Jan;79:104082. doi: 10.1016/j.jddst.2022.104082. Epub 2022 Dec 13. PMID: 36530548; PMCID: PMC9745979.

Özkan B, Altuntaş E, Ünlü Ü, Doğan HH, Özsoy Y, ÇakırKoç R. Development of an Antiviral Ion-Activated In Situ Gel Containing 18β-Glycyrrhetinic Acid: A Promising Alternative against Respiratory Syncytial Virus. Pharmaceutics. 2023 Jul 31;15(8):2055. doi: 10.3390/pharmaceutics15082055. PMID: 37631269; PMCID: PMC10458153.

Chen S, Qiu Q, Wang D, She D, Yin B, Gu G, Chai M, Heo DN, He H, Wang J. Dual-sensitive drug-loaded hydrogel system for local inhibition of post-surgical glioma recurrence. J Control Release. 2022 Sep;349:565-579. doi: 10.1016/j.jconrel.2022.07.011. Epub 2022 Jul 22. PMID: 35835399.

Bakhrushina EO, Mikhel IB, Pyzhov VS, Demina NB, Krasnyuk II Jr, Krasnyuk II. Development of In Situ Intranasal System Based on Chitosan Formate. Bull Exp Biol Med. 2023 Jan;174(3):337-340. doi: 10.1007/s10517-023-05704-6. Epub 2023 Feb 1. PMID: 36723743.

Mikhel IB, Bakhrushina EO, Petrusevich DA, Nedorubov AA, Appolonova SA, Moskaleva NE, Demina NB, Kosenkova SI, Parshenkov MA, Krasnyuk II Jr, Krasnyuk II. Development of an Intranasal In Situ System for Ribavirin Delivery: In Vitro and In Vivo Evaluation. Pharmaceutics. 2024 Aug 26;16(9):1125. doi: 10.3390/pharmaceutics16091125. PMID: 39339163; PMCID: PMC11435039.

Mikhel I, Bakhrushina E, Stepanova O, Prilepskaya S, Kosenkov D, Belyatskaya A, Evzikov G, Demina N, Krasnyuk I Jr, Krasnyuk I. Ribavirin in Modern Antitumor Therapy: Prospects for Intranasal Administration. Curr Drug Deliv. 2024 Aug 26. doi: 10.2174/0115672018305548240614113451. Epub ahead of print. PMID: 39192644.

Tao Y, Zhang Y, Xia T, Lin N. Melt Compounding of Poly(lactic acid)-Based Composites: Blending Strategies, Process Conditions, and Mechanical Properties. Macromol Rapid Commun. 2024 Oct;45(20):e2400380. doi: 10.1002/marc.202400380. Epub 2024 Jul 16. PMID: 39012274.

Olkhov AA, Mastalygina EE, Ovchinnikov VA, Kurnosov AS, Popov AA, Iordanskii AL. Biological and Oxidative Degradation of Ultrathin-Fibrous Nonwovens Based on Poly(lactic Acid)/Poly(3-Hydroxybutyrate) Blends. Int J Mol Sci. 2023 Apr 28;24(9):7979. doi: 10.3390/ijms24097979. PMID: 37175689; PMCID: PMC10178885.

Nyambura CW, Nance E, Pfaendtner J. Examining the Effect of Polymer Extension on Protein-Polymer Interactions That Occur during Formulation of Protein-Loaded Poly(lactic acid-co-glycolic acid)-polyethylene Glycol Nanoparticles. Polymers (Basel). 2022 Nov 4;14(21):4730. doi: 10.3390/polym14214730. PMID: 36365724; PMCID: PMC9656384.

Woods SE, Tinkler JD, Bensabeh N, Palà M, Martin SJ, Martin-Fabiani I, Lligadas G, Hatton FL. Temperature-Responsive Lactic Acid-Based Nanoparticles by RAFT-Mediated Polymerization-Induced Self-Assembly in Water. ACS Sustain Chem Eng. 2023 Jun 26;11(27):9979-9988. doi: 10.1021/acssuschemeng.3c01112. PMID: 37448723; PMCID: PMC10337250.

Capuana E, Lopresti F, Ceraulo M, La Carrubba V. Poly-l-Lactic Acid (PLLA)-Based Biomaterials for Regenerative Medicine: A Review on Processing and Applications. Polymers (Basel). 2022 Mar 14;14(6):1153. doi: 10.3390/polym14061153. PMID: 35335484; PMCID: PMC8955974.

Cucoveica O, Stadoleanu C, Bertsch C, Triaud R, Condriuc IP, Atanase LI, Delaite C. Colloidal Characteristics of Poly(L-Lactic Acid)-b-Poly (ε-Caprolactone) Block Copolymer-Based Nanoparticles Obtained by an Emulsification/Evaporation Method. Polymers (Basel). 2024 Sep 28;16(19):2748. doi: 10.3390/polym16192748. PMID: 39408458; PMCID: PMC11479068.

Wanasathop A, Murawsky M, Li SK. Modification of small dissolution chamber system for long-acting periodontal drug product evaluation. Int J Pharm. 2022 Apr 25;618:121646. doi: 10.1016/j.ijpharm.2022.121646. Epub 2022 Mar 6. PMID: 35259441; PMCID: PMC9136688.

Najahi-Missaoui W, Arnold RD, Cummings BS. Safe Nanoparticles: Are We There Yet? Int J Mol Sci. 2020 Dec 31;22(1):385. doi: 10.3390/ijms22010385. PMID: 33396561; PMCID: PMC7794803.

Kłusak A, Gazińska MA. Recent progress of poly(glycerol adipate)-based network materials toward tissue engineering applications. Front BioengBiotechnol. 2024 Sep 17;12:1447340. doi: 10.3389/fbioe.2024.1447340. PMID: 39355275; PMCID: PMC11442387.

Jacob PL, Brugnoli B, Del Giudice A, Phan H, Chauhan VM, Beckett L, Gillis RB, Moloney C, Cavanagh RJ, Krumins E, Reynolds-Green M, Lentz JC, Conte C, CuzzucoliCrucitti V, Couturaud B, Galantini L, Francolini I, Howdle SM, Taresco V. Poly (diglycerol adipate) variants as enhanced nanocarrier replacements in drug delivery applications. J Colloid Interface Sci. 2023 Jul;641:1043-1057. doi: 10.1016/j.jcis.2023.03.124. Epub 2023 Mar 22. PMID: 36996683.

Brugnoli B, Perna G, Alfano S, Piozzi A, Galantini L, Axioti E, Taresco V, Mariano A, Scotto d'Abusco A, Vecchio Ciprioti S, Francolini I. Nanostructured Poly-l-lactide and Polyglycerol Adipate Carriers for the Encapsulation of Usnic Acid: A Promising Approach for Hepatoprotection. Polymers (Basel). 2024 Feb 3;16(3):427. doi: 10.3390/polym16030427. PMID: 38337316; PMCID: PMC10857334.

Taresco V, Tulini I, Francolini I, Piozzi A. Polyglycerol Adipate-Grafted Polycaprolactone Nanoparticles as Carriers for the Antimicrobial Compound Usnic Acid. Int J Mol Sci. 2022 Nov 18;23(22):14339. doi: 10.3390/ijms232214339. PMID: 36430814; PMCID: PMC9693002.

Suksiriworapong J, Achayawat C, Juangrattanakamjorn P, Taresco V, Crucitti VC, Sakchaisri K, Bunsupa S. Modification of Poly(Glycerol Adipate) with Tocopherol and Cholesterol Modulating Nanoparticle Self-Assemblies and Cellular Responses of Triple-Negative Breast Cancer Cells to SN-38 Delivery. Pharmaceutics. 2023 Aug 8;15(8):2100. doi: 10.3390/pharmaceutics15082100. PMID: 37631315; PMCID: PMC10459774.

Trifunović J, Borčić V, Vukmirović S, Vasović V, Mikov M. Bile acids and their oxo derivatives: environmentally safe materials for drug design and delivery. Drug Chem Toxicol. 2017 Oct;40(4):397-405. doi: 10.1080/01480545.2016.1244680. Epub 2016 Oct 26. PMID: 27780364.

Nemati M, Fathi-Azarbayjani A, Al-Salami H, Roshani Asl E, Rasmi Y. Bile acid-based advanced drug delivery systems, bilosomes and micelles as novel carriers for therapeutics. Cell BiochemFunct. 2022 Aug;40(6):623-635. doi: 10.1002/cbf.3732. Epub 2022 Jul 13. PMID: 35830577.

Kaurav H, Tripathi M, Kaur SD, Bansal A, Kapoor DN, Sheth S. Emerging Trends in Bilosomes as Therapeutic Drug Delivery Systems. Pharmaceutics. 2024 May 23;16(6):697. doi: 10.3390/pharmaceutics16060697. PMID: 38931820; PMCID: PMC11206586.

Deng F, Bae YH. Effect of modification of polystyrene nanoparticles with different bile acids on their oral transport. Nanomedicine. 2023 Feb;48:102629. doi: 10.1016/j.nano.2022.102629. Epub 2022 Nov 21. PMID: 36410698; PMCID: PMC9918699.

Moroishi K, Nakamoto M, Matsusaki M. Fabrication of Molecular Blocks with High Responsiveness to the Cancer Microenvironment by Ursodeoxycholic Acid. Biomacromolecules. 2023 May 8;24(5):2369-2379. doi: 10.1021/acs.biomac.3c00235. Epub 2023 Apr 13. PMID: 37053088.

Faustino C, Serafim C, Rijo P, Reis CP. Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents. Expert Opin Drug Deliv. 2016 Aug;13(8):1133-48. doi: 10.1080/17425247.2016.1178233. Epub 2016 May 2. PMID: 27102882.

Mondal D, Mandal RP, De S. Addressing the Superior Drug Delivery Performance of Bilosomes─A Microscopy and Fluorescence Study. ACS Appl Bio Mater. 2022 Aug 15;5(8):3896-3911. doi: 10.1021/acsabm.2c00435. Epub 2022 Aug 4. PMID: 35924346.

Jones M, Ionescu CM, Walker D, Wagle SR, Kovacevic B, Chester J, Foster T, Johnston E, Kuthubutheen J, Brown D, Atlas MD, Mikov M, Mooranian A, Al-Salami H. Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions. Int J Mol Sci. 2022 Jan 13;23(2):836. doi: 10.3390/ijms23020836. PMID: 35055022; PMCID: PMC8775521.

Mooranian A, Raj Wagle S, Kovacevic B, Takechi R, Mamo J, Lam V, Watts GF, Mikov M, Golocorbin-Kon S, Stojanovic G, Al-Sallami H, Al-Salami H. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Sci Rep. 2020 Jan 9;10(1):106. doi: 10.1038/s41598-019-53999-1. PMID: 31919411; PMCID: PMC6952395.

Gvoic M, Vukmirovic S, Al-Salami H, Mooranian A, Mikov M, Stankov K. Bile acids as novel enhancers of CNS targeting antitumor drugs: a comprehensive review. Pharm Dev Technol. 2021 Jul;26(6):617-633. doi: 10.1080/10837450.2021.1916032. Epub 2021 Apr 22. PMID: 33882793.

Zhou T, Liu Y, Lei K, Liu J, Hu M, Guo L, Guo Y, Ye Q. A "Trojan Horse" Strategy: The Preparation of Bile Acid-Modifying Irinotecan Hydrochloride Nanoliposomes for Liver-Targeted Anticancer Drug Delivery System Study. Molecules. 2023 Feb 7;28(4):1577. doi: 10.3390/molecules28041577. PMID: 36838565; PMCID: PMC9963329.

Alghurabi H, Jassim Muhammad H, Tagami T, Ogawa K, Ozeki T. Optimization, cellular uptake, and in vivo evaluation of Eudragit S100-coated bile salt-containing liposomes for oral colonic delivery of 5-aminosalicylic acid. Int J Pharm. 2023 Dec 15;648:123597. doi: 10.1016/j.ijpharm.2023.123597. Epub 2023 Nov 10. PMID: 37952559.

Deng F, Bae YH. Bile acid transporter-mediated oral drug delivery. J Control Release. 2020 Nov 10;327:100-116. doi: 10.1016/j.jconrel.2020.07.034. Epub 2020 Jul 22. PMID: 32711025; PMCID: PMC7606772.

Kim KS, Na K, Bae YH. Nanoparticle oral absorption and its clinical translational potential. J Control Release. 2023 Aug;360:149-162. doi: 10.1016/j.jconrel.2023.06.024. Epub 2023 Jun 23. PMID: 37348679.

Li H, Chen Y, Li Z, Li X, Jin Q, Ji J. Hemoglobin as a Smart pH-Sensitive Nanocarrier To Achieve Aggregation Enhanced Tumor Retention. Biomacromolecules. 2018 Jun 11;19(6):2007-2013. doi: 10.1021/acs.biomac.8b00241. Epub 2018 Mar 7. PMID: 29498829.

Couroux P, Brkovic A, Vittitow JL, Israel RJ, Pamidi C, Patel J, Barakat M. A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin. Clin Transl Sci. 2022 Sep;15(9):2159-2171. doi: 10.1111/cts.13350. Epub 2022 Jun 24. PMID: 35677972; PMCID: PMC9468560.

Elalfy H, Besheer T, El-Mesery A, El-Gilany AH, Soliman MA, Alhawarey A, Alegezy M, Elhadidy T, Hewidy AA, Zaghloul H, Neamatallah MAM, Raafat D, El-Emshaty WM, Abo El Kheir NY, El-Bendary M. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19. J Med Virol. 2021 May;93(5):3176-3183. doi: 10.1002/jmv.26880. Epub 2021 Mar 11. PMID: 33590901; PMCID: PMC8014583.

Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, Wentzel H, Hill A, Sadeghi A, Freeman J, Salmanzadeh S, Esmaeilian H, Mobarak M, Tabibi R, Jafari Kashi AH, Lotfi Z, Talebzadeh SM, Wickramatillake A, Momtazan M, HajizadehFarsani M, Marjani S, Mobarak S. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19. J AntimicrobChemother. 2020 Nov 1;75(11):3366-3372. doi: 10.1093/jac/dkaa331. PMID: 32812051; PMCID: PMC7529105.

Dumont EF, Oliver AJ, Ioannou C, Billiard J, Dennison J, van den Berg F, Yang S, Chandrasekaran V, Young GC, Lahiry A, Starbuck DC, Harrell AW, Georgiou A, Hopchet N, Gillies A, Baker SJ. A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study. Antimicrob Agents Chemother. 2020 Apr 21;64(5):e02267-19. doi: 10.1128/AAC.02267-19. PMID: 32071044; PMCID: PMC7179635.

Casaos J, Gorelick NL, Huq S, Choi J, Xia Y, Serra R, Felder R, Lott T, Kast RE, Suk I, Brem H, Tyler B, Skuli N. The Use of Ribavirin as an Anticancer Therapeutic: Will It Go Viral? Mol Cancer Ther. 2019 Jul;18(7):1185-1194. doi: 10.1158/1535-7163.MCT-18-0666. PMID: 31263027.

Toader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC, Chin CN, Dirksen A, Du B, Duvall JR, Higgins S, Kozytska MV, Bellovoda K, Faircloth C, Lee D, Li F, Qin L, Routhier C, Shaw P, Stevenson CA, Wang J, Wongthida P, Ter-Ovanesyan E, Ditty E, Bradley SP, Xu L, Yin M, Yurkovetskiy AV, Mosher R, Damelin M, Lowinger TB. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Mol Cancer Ther. 2023 Sep 5;22(9):999-1012. doi: 10.1158/1535-7163.MCT-22-0786. PMID: 37294948; PMCID: PMC10477829.

Wong CW, Wong E, Metselaar JM, Storm G, Wong TT. Liposomal drug delivery system for anti-inflammatory treatment after cataract surgery: a phase I/II clinical trial. Drug DelivTransl Res. 2022 Jan;12(1):7-14. doi: 10.1007/s13346-021-00912-x. Epub 2021 Feb 10. PMID: 33569720.